Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Proteome Sciences plc    PRM   GB0003104196

 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
05/22/2017 05/23/2017 05/24/2017 05/25/2017 05/26/2017 Date
5.13(c) 4.875(c) 4.875(c) 4.925(c) 5.25(c) Last
2 320 028 3 423 132 186 628 29 763 700 Volume
-2.29% -4.97% 0.00% +1.03% +6.60% Change
More quotes
Financials ( GBP)
Sales 2017 4,10 M
EBIT 2017 -1,60 M
Net income 2017 -
Debt 2017 -
Yield 2017 -
Sales 2018 5,50 M
EBIT 2018 -0,10 M
Net income 2018 -
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 52,50
Capi. / Sales2017 3,77x
Capi. / Sales2018 2,81x
Capitalization 15,5 M
More Financials
Company
Proteome Sciences Plc is engaged in applied proteomics and peptidomics services and applications.It offers proprietary technologies for protein and peptide biomarker discovery, validation, and assay development.The company focuses on developing proprietary protein biomarkers for neurological... 
More about the company
Latest news on PROTEOME SCIENCES PLC
04/25 PROTEOME SCIENCES : AGM Statement and Result of AGM
04/25 PROTEOME SCIENCES : Trading Remains In Line With Expectations
04/03 PROTEOME SCIENCES : Appoints Richard Dennis Chief Commercial Officer
04/03 PROTEOME SCIENCES : Appointment of Richard Dennis as Chief Commercial Officer
03/31 PROTEOME SCIENCES : Annual Report and Accounts 2016
03/28 PROTEOME SCIENCES : Says "Much Yet To Do" As Loss Narrows In 2016
03/28 PROTEOME SCIENCES : Preliminary results for the year ended 31 December 2016 Noti..
03/23PROTEOME SCIENCES PLC : annual earnings release
02/09 PROTEOME SCIENCES : Trading Update and Notice of Results
02/09 PROTEOME SCIENCES : Expects Narrowed Loss, Appoints Commercial Officer
More news
Sector news : Bio Therapeutic Drugs
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
More sector news : Bio Therapeutic Drugs
Latest Tweets
03/31Proteome Sciences : Annual Report and Accounts 2016  
03/28Proteome Sciences revenue rises in full year results  
03/28Proteome Sciences plc's corporate rating reiterated at FinnCap. GBX 12 PT.  
03/28Proteome Sciences : Preliminary results for the year ended 31 December 2016 N.. 
02/24Proteome Sciences plc's corporate rating reiterated at FinnCap. GBX 12 PT.  
More tweets
Qtime:7
Advertisement
Chart PROTEOME SCIENCES PLC
Duration : Period :
Proteome Sciences plc Technical Analysis Chart | PRM | GB0003104196 | 4-Traders
Full-screen chart
Technical analysis trends PROTEOME SCIENCES...
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jeremy Rupert Michael Haigh Chief Executive Officer & Executive Director
Christopher D. J. Pearce Executive Chairman
Ian H. Pike Chief Operating Officer & Executive Director
Geoffrey John Ellis Secretary, Executive & Finance Director
Malcolm Ward Chief Technical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PROTEOME SCIENCES PLC-4.55%20
AMGEN, INC.6.02%113 994
CELGENE CORPORATION0.86%91 185
GILEAD SCIENCES, INC.-9.93%84 284
REGENERON PHARMACEUTIC..24.14%48 380
ACTELION LTD26.30%30 602
More Results